Navigation Links
3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
Date:11/21/2013

MENLO PARK, Calif., Nov. 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc. (3-V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced that William McCulloch, MB, ChB, FRCP, FFPM has joined the company as Chief Medical Officer.  Dr. McCulloch brings nearly three decades of senior research and development experience to 3-V, including an extensive preclinical and clinical development background in oncology.  Dr. McCulloch will be responsible for 3-V's clinical, medical affairs and regulatory functions, overseeing strategy and implementation for the advancement of 3-V's pipeline of proprietary therapeutic candidates. 

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"With a thorough understanding of the oncology field and many years of relevant experience in the pharmaceutical and biotech industries, Bill brings significant breadth and depth to our executive team," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  "Bill will provide invaluable leadership as we move forward in the clinical evaluation of our lead FASN inhibitor in patients with solid tumors."

"I look forward to leading the development of TVB-2640, a promising fatty acid synthase inhibitor, through clinical development. Our first study will explore safety, dosing levels and initial anti-cancer activity in patients with advanced solid tumors," said Dr. McCulloch.  "I was attracted to this position based on the potential of TVB-2640, as well as 3-V's wealth of opportunity based on its drug discovery capabilities, leadership team and backing from top venture capital firms."

Dr. McCulloch previously served as Chief Medical Officer at Gloucester Pharmaceuticals, Inc., where he led the regulatory s
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Simpson Eldredge Hersh & Jardine, P.C., one of the nations, ... lawsuit in Ohio against DePuy Orthopaedics, Inc. on behalf of ... ASR XL Acetabular System hip replacement. On August ... Johnson (NYSE: JNJ ), announced a voluntary recall ...
... Sept. 28 Cobalis Corp. (Pink Sheets: ... Call to provide investors and shareholders with further details and ... and legal issues. Shareholders and investors MUST RSVP ... October 5, 2010 at 1:15pm Pacific Time. Interested parties may ...
Cached Medicine Technology:Class Action Lawsuit Filed Against DePuy Orthopaedics, Inc. 2Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2
(Date:7/28/2014)... According to the Heartburn No More PDF review recently updated ... people get rid of acid reflux naturally. This ... and acid reflux. In addition, inside this book, people will ... for reflux disease. , Vkool informs in its review ... of reflux disease naturally without medications. The book also instructs ...
(Date:7/28/2014)... Shore Points Capital announced today that ... Loftware, Inc., through a recapitalization of the Company led ... lead investor in Loftware for over nine years, a ... international provider of enterprise level software solutions for supply ... investment for us, and we are proud of everything ...
(Date:7/27/2014)... 28, 2014 Hyaluronic Acid can hold ... the key to the power of Hyaluronic Serums. , ... Heshelow, founder of Sublime Beauty®. "But like collagen, it ... as ours improves skin moisture-retention and radiance." , ... to a healthy and beautiful look. Key Ingredients in ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The inaugural ... Latinos demonstrate their passion for protecting our environment and ... in the Southwest, will go on hiking or camping ... to show their support for permanently protecting our land, ... sharing the Latino community’s perspective on the environment like ...
Breaking Medicine News(10 mins):Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3
... MINRAD International, Inc. (Amex: BUF ) today ... NYSE Alternext US LLC (the "Exchange") stating that a ... September 30, 2008, indicated the Company was not in ... (the "Company Guide"), namely Section 1003(a)(i), with stockholders, equity ...
... now show their drugs don,t increase chances of cardiac ... U.S. Food and Drug Administration is now asking all ... medications to undertake studies that determine whether they cause ... comes on the heels of reports that two commonly ...
... concerns about costs and increased promiscuity among teenagers appear ... human papilloma virus (HPV) to prevent life-threatening diseases, according ... Public Health. , There is an ongoing public ... to prevent against genital warts and cervical cancer, but ...
... 17 Paramedics and emergency medical technicians (EMTs) employed ... and members of Teamsters Local 375 attended the company,s ... Employee shareholders expressed their frustration with the company,s ... a new contract in the greater Buffalo, New York ...
... Growing Jacksonville Market , , ... Company, Inc. (Nasdaq: IPCM ), a leading national ... North Florida Hospitalists (NFH) and Orange Park Hospitalists (OPH) of ... greater Jacksonville market, where the IPC has already established a ...
... /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences ... services, today reported financial and operation results for the ... 2008. The Company announced a net loss of $3,568,321 ... October 31, 2008, and a net loss of $13,833,978 ...
Cached Medicine News:Health News:MINRAD Receives Notice of Failure to Satisfy a Continued Listing Rule from NYSE Alternext 2Health News:MINRAD Receives Notice of Failure to Satisfy a Continued Listing Rule from NYSE Alternext 3Health News:FDA Wants New Diabetes Drugs Tested for Heart Risks 2Health News:Fears of promiscuity pose barrier to cervical cancer vaccinations 2Health News:IPC The Hospitalist Company Acquires Two Florida Practices 2Health News:DiagnoCure announces fourth quarter 2008 and year-end results 2Health News:DiagnoCure announces fourth quarter 2008 and year-end results 3Health News:DiagnoCure announces fourth quarter 2008 and year-end results 4Health News:DiagnoCure announces fourth quarter 2008 and year-end results 5Health News:DiagnoCure announces fourth quarter 2008 and year-end results 6Health News:DiagnoCure announces fourth quarter 2008 and year-end results 7
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
... concise yet complete eTextbook of standard ... disease. In addition to the Redi-Reference ... full desktop version is included at ... the electronic textbook, Redi-Reference provides periodic ...
ECG pocket is a handy reference for identifying common ECG findings....
... involved with healthcare decisions to keep up ... in their field of interest - a ... the volume of evidence increases. Cochrane Reviews ... single source available for continually updated evidence-based ...
Medicine Products: